Adipo is a privately held, late-stage, preclinical biopharmaceutical company developing a breakthrough approach to treat the dual epidemics of obesity and Type 2 diabetes. Adipo has identified a lead asset, ADPO-002, that combines a notch inhibitor with novel nanoparticle technology. ADPO-002 is specifically designed to infiltrate and release the active ingredient inside the cellular structure of white adipose tissue, which results in mitochondrial biogenesis and the beiging of white adipose tissue. Meng Deng is the founder and president of Adipo Therapeutics. He also is an associate professor in Purdue University’s Department of Agricultural and Biological Engineering, Weldon School of Biomedical Engineering and School of Materials Engineering.